Naing Lin Shan
MBBS, PhD, MS
Postdoctoral Associate
Research & Publications
Biography
News
Coauthors
Selected Publications
- Intratumour heterogeneity, from hypothesis to the clinicShan NL, Kahn A, Pusztai L. Intratumour heterogeneity, from hypothesis to the clinic. British Journal Of Cancer 2022, 128: 459-460. PMID: 36216884, PMCID: PMC9938204, DOI: 10.1038/s41416-022-02008-w.
- Comprehensive Analysis of Metabolic Isozyme Targets in CancerMarczyk M, Gunasekharan V, Casadevall D, Qing T, Foldi J, Sehgal R, Shan NL, Blenman KRM, O'Meara TA, Umlauf S, Surovtseva YV, Muthusamy V, Rinehart J, Perry RJ, Kibbey R, Hatzis C, Pusztai L. Comprehensive Analysis of Metabolic Isozyme Targets in Cancer. Cancer Research 2022, 82: 1698-1711. PMID: 35247885, PMCID: PMC10883296, DOI: 10.1158/0008-5472.can-21-3983.
- Molecular differences between younger versus older ER-positive and HER2-negative breast cancersQing T, Karn T, Rozenblit M, Foldi J, Marczyk M, Shan N, Blenman K, Holtrich U, Kalinsky K, Meric-Bernstam F, Pusztai L. Molecular differences between younger versus older ER-positive and HER2-negative breast cancers. Npj Breast Cancer 2022, 8: 119. PMID: 36344517, PMCID: PMC9640562, DOI: 10.1038/s41523-022-00492-0.
- Analysis of the Transcriptome: Regulation of Cancer Stemness in Breast Ductal Carcinoma In Situ by Vitamin D CompoundsShan N, Minden A, Furmanski P, Bak M, Cai L, Wernyj R, Sargsyan D, Cheng D, Wu R, Kuo H, Li S, Fang M, Maehr H, Kong A, Suh N. Analysis of the Transcriptome: Regulation of Cancer Stemness in Breast Ductal Carcinoma In Situ by Vitamin D Compounds. Cancer Prevention Research 2020, 13: 673-686. PMID: 32467291, PMCID: PMC7415686, DOI: 10.1158/1940-6207.capr-19-0566.
- Vitamin D compounds inhibit cancer stem-like cells and induce differentiation in triple negative breast cancerShan N, Wahler J, Lee H, Bak M, Gupta S, Maehr H, Suh N. Vitamin D compounds inhibit cancer stem-like cells and induce differentiation in triple negative breast cancer. The Journal Of Steroid Biochemistry And Molecular Biology 2016, 173: 122-129. PMID: 27923595, PMCID: PMC5459680, DOI: 10.1016/j.jsbmb.2016.12.001.
- Breast cancer stem cells: A review of their characteristics and the agents that affect themShan N, Shin Y, Yang G, Furmanski P, Suh N. Breast cancer stem cells: A review of their characteristics and the agents that affect them. Molecular Carcinogenesis 2021, 60: 73-100. PMID: 33428807, PMCID: PMC7855917, DOI: 10.1002/mc.23277.
- Abstract PD9-09: Molecular differences between younger versus older estrogen receptor positive/human epidermal growth factor receptor-2 negative breast cancersQing T, Karn T, Rozenblit M, Foldi J, Marczyk M, Shan N, Blenman K, Holtrich U, Kalinsky K, Meric-Bernstam F, Pusztai L. Abstract PD9-09: Molecular differences between younger versus older estrogen receptor positive/human epidermal growth factor receptor-2 negative breast cancers. Cancer Research 2023, 83: pd9-09-pd9-09. DOI: 10.1158/1538-7445.sabcs22-pd9-09.
- Abstract P5-17-01: Targeting Acetyl-CoA carboxylase in pre-clinical breast cancer modelsFoldi J, Marczyk M, Gunasekharan V, Qing T, Sehgal R, Shan N, Muthusamy V, Umlau S, Surovtseva Y, Kibbey R, Pusztai L. Abstract P5-17-01: Targeting Acetyl-CoA carboxylase in pre-clinical breast cancer models. Cancer Research 2022, 82: p5-17-01-p5-17-01. DOI: 10.1158/1538-7445.sabcs21-p5-17-01.
- Abstract 5067: Identification of key drivers of cancer stemness and progression regulated by vitamin D compounds in ductal carcinoma in situ breast cancerShan N, Bak M, Cai L, Wernyj R, Sargsyan D, Cheng D, Minden A, Kong A, Suh N. Abstract 5067: Identification of key drivers of cancer stemness and progression regulated by vitamin D compounds in ductal carcinoma in situ breast cancer. 2019, 5067-5067. DOI: 10.1158/1538-7445.sabcs18-5067.
- Abstract 5067: Identification of key drivers of cancer stemness and progression regulated by vitamin D compounds in ductal carcinoma in situ breast cancerShan N, Bak M, Cai L, Wernyj R, Sargsyan D, Cheng D, Minden A, Kong A, Suh N. Abstract 5067: Identification of key drivers of cancer stemness and progression regulated by vitamin D compounds in ductal carcinoma in situ breast cancer. Cancer Research 2019, 79: 5067-5067. DOI: 10.1158/1538-7445.am2019-5067.
- KPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer CellsCordover E, Wei J, Patel C, Shan N, Gionco J, Sargsyan D, Wu R, Cai L, Kong A, Jacinto E, Minden A. KPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells. Chemical Research In Toxicology 2019, 33: 482-491. PMID: 31876149, PMCID: PMC9316853, DOI: 10.1021/acs.chemrestox.9b00376.
- Abstract PO3-25-08: Artificial Intelligence-based screening of small molecule inhibitors of phosphoenolpyruvate carboxykinase 2 (PCK2), a novel cancer therapeutic targetHoyo A, Shan N, Lin H, Campos G, Ahmed M, Umlauf S, Cardone R, Surovtseva Y, Gunasekharan V, pusztai L. Abstract PO3-25-08: Artificial Intelligence-based screening of small molecule inhibitors of phosphoenolpyruvate carboxykinase 2 (PCK2), a novel cancer therapeutic target. Cancer Research 2024, 84: po3-25-08-po3-25-08. DOI: 10.1158/1538-7445.sabcs23-po3-25-08.
- Abstract PO5-14-05: Circulating tumor DNA fraction correlates with residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer patientsShan N, Gould B, Blenman K, Foldi J, Du P, Zhang F, Walsh M, Pusztai L. Abstract PO5-14-05: Circulating tumor DNA fraction correlates with residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer patients. Cancer Research 2024, 84: po5-14-05-po5-14-05. DOI: 10.1158/1538-7445.sabcs23-po5-14-05.
- Participation of xCT in melanoma cell proliferation in vitro and tumorigenesis in vivoShin S, Jeong B, Wall B, Li J, Shan N, Wen Y, Goydos J, Chen S. Participation of xCT in melanoma cell proliferation in vitro and tumorigenesis in vivo. Oncogenesis 2018, 7: 86. PMID: 30425240, PMCID: PMC6234219, DOI: 10.1038/s41389-018-0098-7.
- Abstract 276: Targeting cancer stem cells with chemopreventive agents for breast cancer preventionShan N, Yang J, Bak M, Wahler J, Suh N. Abstract 276: Targeting cancer stem cells with chemopreventive agents for breast cancer prevention. Cancer Research 2018, 78: 276-276. DOI: 10.1158/1538-7445.am2018-276.
- Tocopherols inhibit estrogen-induced cancer stemness and OCT4 signaling in breast cancerBak M, Furmanski P, Shan N, Lee H, Bao C, Lin Y, Shih W, Yang C, Suh N. Tocopherols inhibit estrogen-induced cancer stemness and OCT4 signaling in breast cancer. Carcinogenesis 2018, 39: 1045-1055. PMID: 29846560, PMCID: PMC6067126, DOI: 10.1093/carcin/bgy071.